Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae.
This review focuses on the activity of gemifloxacin, a new respiratory fluoroquinolone, against the two most important bacterial pathogens associated with lower respiratory tract infections, namely Streptococcus pneumoniae and Haemophilus influenzae.
Morrissey
Ian
I
GR Micro Ltd., 7-9 William Road, London NW1 3ER, UK. i.morrissey@grmicro.co.uk
Tillotson
Glenn
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D024841:Fluoroquinolones / Q000494:pharmacology* / Q000627:therapeutic use; D000077735:Gemifloxacin; D006192:Haemophilus Infections / Q000188:drug therapy / Q000382:microbiology; D006193:Haemophilus influenzae / Q000187:drug effects*; D006801:Humans; D009287:Naphthyridines / Q000494:pharmacology* / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin